A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Our engineered viruses are designed to induce a systemic anti-tumor response due to induction of immunogenic cell death within the tumor microenvironment, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. This is intended to lead to in-situ vaccination against the injected tumor and uninjected distant metastases. Our biological multimodal immunotherapy approach utilizes intratumoral administration of genetically engineered viruses to induce tumor cell death and elicit a systemic anti-tumor response. Local delivery enables us to achieve these effects while aiming to minimize systemic toxicity.
| Metric | TTM | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Revenue | 0 | - | - | - |
| Net Income | -23M | -19M | -36M | -18M |
| EPS | $-0.56 | $-0.65 | $-1.91 | $-1.52 |
| Free Cash Flow | -34M | -33M | -24M | -11M |
| ROIC | -37785.2% | -38.9% | -55.8% | -28.5% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.06 | 0.01 | 0.01 | -0.02 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -41M | -35M | -26M | -14M |
| Operating Margin | 0.0% | - | - | - |
| ROE | -28.4% | -39.4% | -56.3% | - |
| Shares Outstanding | 55M | 29M | 19M | 12M |
| Metric | 2020 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -14M | -26M | -35M | -41M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -18M | -36M | -19M | -23M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -28.5% | -55.8% | -38.9% | N/M |
| ROE | N/A | -56.3% | -39.4% | -28.4% |
| ROA | -46.2% | -40.5% | -24.2% | -26775.3% |
| Cash Flow | ||||
| Op. Cash Flow | -9.1M | -22M | -31M | -34M |
| Free Cash Flow | -11M | -24M | -33M | -34M |
| Owner Earnings | -11M | -25M | -35M | -37M |
| CapEx | 1.5M | 1.8M | 1.3M | 181K |
| Maint. CapEx | 91K | 232K | 778K | 778K |
| Growth CapEx | 1.4M | 1.6M | 519K | 0 |
| D&A | 91K | 232K | 778K | 778K |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.1M | 3.0M | 2.3M | 2.3M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -35M | -82M | -69M | -82M |
| Cash & Equiv. | N/A | N/A | N/A | 87M |
| Long-Term Debt | 483K | 560K | 648K | 648K |
| Debt/Equity | -0.02 | 0.01 | 0.01 | 0.06 |
| Interest Coverage | N/A | N/A | -20.3 | -20.3 |
| Equity | -24M | 64M | 48M | 80M |
| Total Assets | 38M | 89M | 78M | 85K |
| Total Liabilities | 13M | 25M | 30M | 13M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -44M | -80M | -99M | -99M |
| Working Capital | 30M | 80M | 66M | 66M |
| Current Assets | 35M | 85M | 72M | 72M |
| Current Liabilities | 4.7M | 5.4M | 5.6M | 5.6M |
| Per Share Data | ||||
| EPS | -1.52 | -1.91 | -0.65 | -0.56 |
| Owner EPS | -0.97 | -1.34 | -1.19 | -0.67 |
| Book Value | -2.03 | 3.39 | 1.65 | 1.46 |
| Cash Flow/Share | -0.78 | -1.17 | -1.09 | -0.40 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 11.6M | 18.9M | 28.9M | 54.9M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -9.1 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 2.2 | 0.9 | 3.5 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -17.1% | -74.0% | -12.1% |
| Market Cap | N/A | 141M | 44M | 280M |
| Avg. Price | N/A | 9.14 | 3.66 | 5.10 |
| Year-End Price | N/A | 7.45 | 1.53 | 5.10 |
Candel Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Candel Therapeutics, Inc. (CADL) has a 5-year average return on invested capital (ROIC) of -41.1%. This is below average and may indicate limited pricing power.
Candel Therapeutics, Inc. (CADL) has a market capitalization of $280M. It is classified as a small-cap stock.
Candel Therapeutics, Inc. (CADL) does not currently pay a regular dividend.
Candel Therapeutics, Inc. (CADL) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Candel Therapeutics, Inc. (CADL) generated $-33 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Candel Therapeutics, Inc. (CADL) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Candel Therapeutics, Inc. (CADL) reported earnings per share (EPS) of $-0.65 in its most recent fiscal year.
Candel Therapeutics, Inc. (CADL) has a return on equity (ROE) of -39.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Candel Therapeutics, Inc. (CADL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Candel Therapeutics, Inc. (CADL) has a book value per share of $1.65, based on its most recent annual SEC filing.